567516-U

Discovery^® HS F5 (5 µm) HPLC Columns

L × I.D. 15 cm × 4.6 mm, HPLC Column

• Synonym(s): Discovery Pentafluorophenyl PFP HPLC Column
• UNSPSC Code: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

Properties

• product name: Discovery^® HS F5 HPLC Column, 5 μm particle size, L × I.D. 15 cm × 4.6 mm
• material: stainless steel column
• Agency: suitable for USP L43
• product line: Discovery^®
• feature: endcapped
• manufacturer/tradename: Discovery^®
• packaging: 1 ea of
• extent of labeling: 12% Carbon loading
• parameter: ≤70 °C temp. range; 400 bar pressure (5801 psi)
• technique(s): HPLC: suitable; LC/MS: suitable
• L × I.D.: 15 cm × 4.6 mm
• surface area: 300 m²/g
• surface coverage: 4 μmol/m²
• impurities: <10 ppm metals
• matrix: silica gel, high purity, spherical particle platform; fully porous particle
• matrix active group: PFP (pentafluorophenyl) phase
• particle size: 5 μm
• pore size: 120 Å
• operating pH range: 2-8
• application(s): food and beverages
• separation technique: reversed phase

Description

General description

Guidelines for transferring a C18 method to Discovery® HS F5:
Generally, bases are retained longer on the HS F5 than on a C18. Increasing the organic content of a C18 separation 5 to 10 percent will generally provide similar retention on an HS F5. Results with other compounds are highly variable. However, it is generally true that solutes with log P_o/w values less than 2.5 will be retained longer on HS F5 compared to a C18. The degree of difference is highly solute dependent.

The Discovery® HS F5 bonded phase provides reversed-phase separations that are distinctly different from C18 columns. However, compounds will generally elute within the same retention time window, making most C18 methods easily transferable.

Application

• Chromatographic separation of arsenic species with pentafluorophenyl column and application to rice.: This study leverages the Discovery^® HS F5 HPLC Column for advanced arsenic speciation in rice, enhancing food safety analysis and ensuring compliance with health regulations (Baba et al., 2014).


• High-performance liquid chromatographic determination of tiapride and its phase I metabolite in blood plasma using tandem UV photodiode-array and fluorescence detection.: Demonstrates the versatility of the Discovery^® HS F5 HPLC Column in the sensitive and simultaneous detection of tiapride and its metabolites, contributing to therapeutic drug monitoring and pharmacokinetic studies (Nobilis et al., 2011).


• Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry.: Utilizes the Discovery^® HS F5 HPLC Column to accurately measure nicotine and its metabolites in rat brain, providing crucial data for studies on addiction and neuropharmacology (Vieira-Brock et al., 2011).


• Biomarker discovery in biological specimens (plasma, hair, liver and kidney) of diabetic mice based upon metabolite profiling using ultra-performance liquid chromatography with electrospray ionization time-of-flight mass spectrometry.: This research uses the Discovery^® HS F5 HPLC Column to identify biomarkers in various biological samples from diabetic mice, enhancing our understanding of diabetes at the molecular level (Tsutsui et al., 2011).


• Practical analytical approach for the identification of biomarker candidates in prediabetic state based upon metabonomic study by ultraperformance liquid chromatography coupled to electrospray ionization time-of-flight mass spectrometry.: Employs the Discovery^® HS F5 HPLC Column in a metabolomic approach to identify early biomarkers of diabetes, advancing preventive medicine and metabolic research (Tsutsui et al., 2010).

Features and Benefits

• Unique selectivity
• Similar retention to C18 (sometimes requires stronger mobile phase)
• Excellent peak shape
• Stable, low-bleed LC-MS separations
• Scalable separations from 3 to 10μm particle sizes

Recommended products

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany